bi 905711
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 13, 2019 (NCT04137289)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF10B inhibitor
- Hepatitis C virusImmunity, passive
Hepatitis C virus immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05087992 | Phase 1 | Nov 24, 2021 | Boehringer Ingelheim |
| NCT04137289 | Phase 1 | Dec 13, 2019 | Boehringer Ingelheim |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 2 | 2 | 1 | 2019 |
1 organizations
Page 1 / 1